Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Outlook
2023

Annual Industry Ranking And Forecast

Medtech 100: For Edwards Lifesciences' Mike Mussallem, Inspiring People Has Been A Way Of Life

Whatever the new technology, for Mike Mussallem, it always had to start and end with the patient

Executive Summary

Edwards Lifesciences CEO Mike Mussallem has a unique and long-standing perspective of what the medtech industry should be and do. In over two decades, he has built the structural heart disease and critical care monitoring company into one of the global medtech industry’s most effective innovators. That legacy is sure to last after his retirement as CEO in spring 2023.

You may also be interested in...



Getting Personal With Edwards’ Mike Mussallem: Hard Work, Giving Back And Changing The Practice Of Medicine

In this new series titled Getting Personal, we talk to new and veteran senior executives about their journeys to corporate leadership, their motivations, passions, and the peaks and valleys of running a medtech company. Medtech Insight sat down with Mike Mussallem, CEO of Edwards Lifesciences, the leading seller of transcatheter aortic valve replacement (TAVR) devices, at the company’s Irvine, CA-based headquarters.

How COVID Boosted Medtech In The Eyes Of The World

Reaching deep and being resourceful were the in-demand attributes that medtech industry leaders brought to bear when the COVID-19 pandemic stretched health care providers almost to breaking point.

UK Updates Guidance To Reflect EU Medtech Extensions - Pledges Focus On Agility, Innovation

The EU’s decision to extend the Medical Device Regulation transition periods for legacy medical device directives products will be mirrored in the UK, which also continues to evolve its post-Brexit medtech regulatory system.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT147447

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel